Gingko biloba
Gingko Biloba is being studied for its possible use in treating, or preventing, ovarian cancer:
" Researchers in Boston, led by Drs. Bin Ye and Daniel Cramer of Brigham and Women's Hospital, have developed new laboratory and epidemiological evidence that demonstrates, for the first time, that ginkgo biloba appears to lower the risk of developing ovarian cancer.
In a population-based study which involved more than 600 ovarian cancer cases and 640 healthy, matched controls, women who took ginkgo supplements for six months or longer were shown to have a 60 percent lower risk for ovarian cancer.
Ye and his colleagues found that ginkgo, echinacea, St. John's Wort, ginseng, and chondroitin were the most commonly used herbals among study participants. A further analysis of the data showed that ginkgo was the only herb linked to ovarian cancer prevention. The preventive effect was more pronounced in women with non-muncious ovarian cancers, with data showing that ginkgo may reduce the risk of this type of ovarian cancer by 65-70 percent. "Among the mixture of ginkgo chemicals," said Ye, "we found laboratory evidence that ginkgolide A and B--terpene compounds--are the most active components contributing to this protective effect."
Ye's team, which included scientists from Dana-Farber Cancer Institute at Harvard Medical School, Boston University and Linden Bioscience, next took the evidence demonstrated by their population studies to the laboratory. In vitro experiments showed that a low dosage of ginkgolide caused ovarian cancer cells to stop growing. They observed significant cell cycle blockage in non-mucinous ovarian cancer cells. Ginkgolides appeared to be less effective against the mucinous type of ovarian cancer cells."
" Researchers in Boston, led by Drs. Bin Ye and Daniel Cramer of Brigham and Women's Hospital, have developed new laboratory and epidemiological evidence that demonstrates, for the first time, that ginkgo biloba appears to lower the risk of developing ovarian cancer.
In a population-based study which involved more than 600 ovarian cancer cases and 640 healthy, matched controls, women who took ginkgo supplements for six months or longer were shown to have a 60 percent lower risk for ovarian cancer.
Ye and his colleagues found that ginkgo, echinacea, St. John's Wort, ginseng, and chondroitin were the most commonly used herbals among study participants. A further analysis of the data showed that ginkgo was the only herb linked to ovarian cancer prevention. The preventive effect was more pronounced in women with non-muncious ovarian cancers, with data showing that ginkgo may reduce the risk of this type of ovarian cancer by 65-70 percent. "Among the mixture of ginkgo chemicals," said Ye, "we found laboratory evidence that ginkgolide A and B--terpene compounds--are the most active components contributing to this protective effect."
Ye's team, which included scientists from Dana-Farber Cancer Institute at Harvard Medical School, Boston University and Linden Bioscience, next took the evidence demonstrated by their population studies to the laboratory. In vitro experiments showed that a low dosage of ginkgolide caused ovarian cancer cells to stop growing. They observed significant cell cycle blockage in non-mucinous ovarian cancer cells. Ginkgolides appeared to be less effective against the mucinous type of ovarian cancer cells."
0 Comments:
